December 12th2013    Veracity Network’s XT250 Verifies World Health Organization Counterfeit Estimate of US Rx Supply Chain
The XT250 System's material analysis data indicates 3.5% of receivables and 6.5% returns within these pharmaceutical distributor end users are likely counterfeit products or fraudulent medications.


September 12th 2013    Identifying Imported Counterfeit Drugs

"Authenticating Medications"







December 12, 2013  Veracity Network’s XT250 Verifies World Health Organization Counterfeit Estimate of US Rx Supply Chain


Veracity Network, Inc. headquartered in Melbourne, Florida, reports that based on their usage data from end user XT250 systems, they can confirm that the World Health Organization’s (WHO) estimate of 1% of the United States pharmaceutical supply chain being counterfeit is reasonably accurate.


Veracity Network’s XT250 Pharmaceutical Screening System verifies and authenticates materials within its sealed, unit of sale container. The standalone system has been tested with several pharmaceutical distribution companies that distribute pharmaceuticals throughout the United States.  The XT250 is the only technology that can accurately authenticate pharmaceuticals within the supply chain without damaging the product or packaging and is the only materials analysis technology that can keep up with the tremendous flow of drugs throughout the supply chain. 


From the data, Veracity Network is learning that authentication rejection/failure rates vary between pharmaceutical products, and even within a given pharmaceutical product the rejection rates can vary significantly over time. In some cases isolated bottles have been rejected, while in other cases entire lots have been rejected. 


Veracity Network’s data validates that the members of the pharmaceutical supply chain (manufacturers, distributors and dispensers) should be utilizing authentication technology to screen as many pharmaceuticals as possible, as often as possible. Currently many regulatory officials have been advocating more frequent inspections at foreign manufacturing facilities as the primary solution to the problem of poor manufacturing and counterfeit medications in the supply chain. While inspections are needed, given the sheer quantity of places to inspect and global nature of these sites, inspectors have little chance of catching counterfeits. In addition, Veracity Network’s data suggests that counterfeits are inserted at a multitude of sources all along the supply chain. The point of production is not the primary starting point for fake medications. Verification and authentication at each point along the supply chain is the most effective way to detect and interdict fraudulent and counterfeit pharmaceuticals.



back to top



September 12th, 2013   Identifying Imported Counterfeit Drugs



A Florida-based company has begun providing a service which can detect counterfeit drugs in the U.S. pharmaceutical supply chain. Veracity Network, Inc. developed a system to identify dangerous pharmaceuticals in circulation to protect the public by authenticating these medications before they reach the consumer.


The threat of Americans swallowing counterfeit medications is increasing each year. The World Health Organization has stated trade in fake medicines is more prevalent in countries with weak drug regulation and enforcement, scarcity or erratic supply of basic medicines, unregulated markets and  affordable prices. But as counterfeiting becomes more sophisticated, these products are increasingly present even in better controlled markets. Some undeveloped nations see regions where counterfeit pharmaceutical rates are as high as 30%.  To protect the public we need to take action and make sure patients are receiving safe medications.


Veracity Network's system authenticates a drug while still in its sealed container. The “fingerprint” of each drug is completely unique, so questionable medications can be compared to the actual drug’s fingerprint. To do this, an operator places a bottle into the unit and presses the “start” button on a touch screen. The molecular crystal structure of the drug is then examined and compared against stored data to receive a “passed” or “failed” message.  

To date, U.S. Immigration and Customs Enforcement has initiated over 178 criminal investigations of pharmaceutical smuggling. These investigations have targeted over 650 websites and millions of dosage units of counterfeit, adulterated, misbranded and unapproved pharmaceuticals – all available to American consumers.


Veracity Network's system is the first of its kind.




Veracity Network, Inc.


Veracity Network  develops next-generation equipment for material identification. Their patented systems are based on Energy-Dispersive X-Ray Diffraction (EDXRD) technology. The company’s XT250™ System enables testing of powders, pills and entire sealed bottles. The equipment’s superior sample penetration allows the identification of contents inside opaque plastic, cardboard and even metal packaging.


back to top